Gunnar Birgegard

List of Publications by Year
in descending order

74 papers	5,198 citations	201385 27 h-index	85405 71 g-index
77 all docs	77 docs citations	77 times ranked	4295 citing authors

#	Article	IF	Citations
1	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematology,the, 2021, 8, e658-e665.	2.2	17
2	JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling. Journal of Health Economics and Outcomes Research, 2020, 7, 61-70.	0.6	4
3	The European Hematology Exam: The Next Step toward the Harmonization of Hematology Training in Europe. HemaSphere, 2019, 3, e291.	1.2	1
4	Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group. European Journal of Haematology, 2019, 102, 235-240.	1.1	21
5	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. Haematologica, 2018, 103, 51-60.	1.7	58
6	Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leukemia Research, 2018, 74, 105-109.	0.4	13
7	Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial. Blood, 2018, 132, 1762-1762.	0.6	1
8	Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group. Haematologica, 2017, 102, 85-93.	1.7	46
9	Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leukemia Research, 2017, 63, 34-40.	0.4	18
10	The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Cancer, 2016, 122, 1888-1896.	2.0	16
11	The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia. Current Hematologic Malignancy Reports, 2016, 11, 348-355.	1.2	13
12	A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The <scp>PROFOUND</scp> Trial. Pharmacotherapy, 2016, 36, 402-414.	1.2	48
13	CaphosolÂ® mouthwash gives no additional protection against oral mucositis compared to cryotherapy alone in stem cell transplantation. A pilot study. European Journal of Oncology Nursing, 2015, 19, 50-53.	0.9	25
14	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2015, 9, 211-222.	0.6	425
15	Advances and challenges in the management of essential thrombocythemia. Therapeutic Advances in Hematology, 2015, 6, 142-156.	1.1	13
16	Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy. Medical Oncology, 2014, 31, 302.	1.2	32
17	Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica, 2014, 99, 679-687.	1.7	23
18	Does anything work for anaemia in myelofibrosis?. Best Practice and Research in Clinical Haematology, 2014, 27, 175-185.	0.7	10

#	Article	IF	Citations
19	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood, 2014, 123, 3803-3810.	0.6	79
20	Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80ÂYears: An Interim Analysis of the EXELS Study. Clinical Drug Investigation, 2013, 33, 55-63.	1.1	15
21	Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leukemia Research, 2013, 37, 162-168.	0.4	29
22	Pharmacological management of essential thrombocythemia. Expert Opinion on Pharmacotherapy, 2013, 14, 1295-1306.	0.9	4
23	Diagnosis according to World Health Organization determines the long-term prognosis in patients with myeloproliferative neoplasms treated with anagrelide: Results of a prospective long-term follow-up. Hematology, 2013, 18, 8-13.	0.7	23
24	Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency. Blood, 2013, 122, 3439-3439.	0.6	6
25	Myeloproliferative (MPN) Symptom Burden Response Thresholds: Assessment Of MPN-SAF TSS Quartiles As Potential Markers Of Symptom Response. Blood, 2013, 122, 4067-4067.	0.6	6
26	Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4087-4087.	0.6	9
27	Sexuality Challenges, Intimacy, and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG). Blood, 2013, 122, 4088-4088.	0.6	6
28	Myeloproliferative Neoplasm Quality Of Life (MPN-QOL) Study Group: Observational Study Of Quality Of Life and Symptomatic Response In Myelofibrosis Patients Receiving Undergoing Treatment With Conventional Therapy, The Measures Trial and Allogeneic Stem Cell Transplant, The Symptoms Trial. Blood, 2013, 122, 4090-4090.	0.6	7
29	The Myelofibrosis Symptom Burden (MF-SB): An International Phenotypic Cluster Analysis of 329 Patients. Blood, 2012, 120, 1731-1731.	0.6	2
30	Essential Thrombocythemia (ET) and Polycythemia Vera (PV) Symptom Burden: Phenotypic Cluster Analysis Among an International Sample of 1,141 ET and PV Patients. Blood, 2012, 120, 1726-1726.	0.6	4
31	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients. Blood, 2011, 118, 401-408.	0.6	280
32	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. Journal of Clinical Oncology, 2011, 29, 761-770.	0.8	724
33	Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. Journal of Clinical Oncology, 2011, 29, 2410-2415.	0.8	215
34	The Mylelоproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs),. Blood, 2011, 118, 3839-3839.	0.6	4
35	Unexpected 5 Year Survival Benefit in Patients Given Oral Cryotherapy During Conditioning for Stem Cell Transplantation. A Prospective Randomized Study. Blood, 2011, 118, 4559-4559.	0.6	2
36	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. British Journal of Haematology, 2010, 148, 961-963.	1.2	144

#	Article	IF	Citations
37	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. Blood, 2010, 116, 4095-4095.	0.6	5
38	Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients. Blood, 2010, 116, 5053-5053.	0.6	0
39	Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood, 2009, 113, 4829-4833.	0.6	229
40	Physiological response to phlebotomies for autologous transfusion at elective hip-joint surgery. European Journal of Haematology, 2009, 46, 136-139.	1.1	10
41	New perspectives in managing myeloproliferative disorders: focus on the patient. Hematological Oncology, 2009, 27, 5-7.	0.8	0
42	Long-term management of thrombocytosis in essential thrombocythaemia. Annals of Hematology, 2009, 88, 1-10.	0.8	28
43	Managing anemia in lymphoma and multiple myeloma. Therapeutics and Clinical Risk Management, 2008, Volume 4, 527-539.	0.9	17
44	TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders. International Journal of Medical Sciences, 2008, 5, 87-91.	1.1	6
45	Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 2007, 110, 1092-1097.	0.6	808
46	Essential thrombocythaemia treatment options: addressing patientâ€specific needs. European Journal of Haematology, 2007, 79, 27-31.	1.1	5
47	Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment. Medical Oncology, 2007, 24, 63-70.	1.2	19
48	Evaluation of beta globin mRNA as an early marker of haemoglobin response to epoetin treatment. Medical Oncology, 2007, 24, 318-322.	1.2	3
49	Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. European Journal of Haematology, 2006, 77, 378-386.	1.1	97
50	A phase II trial of pegylated interferon Î±-2b therapy for polycythemia vera and essential thrombocythemia. Cancer, 2006, 106, 2397-2405.	2.0	104
51	Anagrelide Treatment in Myeloproliferative Disorders. Seminars in Thrombosis and Hemostasis, 2006, 32, 260-266.	1.5	15
52	Independent Risk Factors for Anemia in Cancer Patients Receiving Chemotherapy: Results from the European Cancer Anaemia Survey. Oncology, 2006, 70, 34-48.	0.9	55
53	Functional Iron Deficiency Effectively Overcome by Adjuvant IV Iron during Epoetin Treatment.. Blood, 2006, 108, 3725-3725.	0.6	0
54	Evaluation of beta Globin mRNA as an Early Marker of Hb Response to Epoetin Treatment.. Blood, 2006, 108, 3750-3750.	0.6	0

#	Article	IF	Citations
55	Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica, 2006, 91, 1281-2.	1.7	26
56	New Guidelines on Anaemia Management in Patients with Cancer: How Do These Affect Clinical Practice?. Oncology, 2005, 69, 17-21.	0.9	90
57	Cancer-Related Anemia: Pathogenesis, Prevalence and Treatment. Oncology, 2005, 68, 3-11.	0.9	156
58	The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer, 2004, 40, 2293-2306.	1.3	749
59	Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica, 2004, 89, 520-7.	1.7	64
60	CIRCADIAN VARIATION OF GRANULOCYTE COLONY-STIMULATING FACTOR LEVELS IN MAN. British Journal of Haematology, 2000, 108, 661-661.	1.2	1
61	Change in student attitudes to medical school after the introduction of problem-based learning in spite of low ratings. Medical Education, 1998, 32, 46-49.	1.1	35
62	Preoperative autologous donation of 6 units of blood during rh-EPO treatment. Canadian Journal of Anaesthesia, 1997, 44, 1315-1318.	0.7	9
63	Improving Awareness of the Psychosocial Needs of the Patienta Training Course for Experienced Cancer Doctors. Acta OncolÃ³gica, 1996, 35, 246-247.	0.8	15
64	Improved Care of Patients with Small Cell Lung Cancer Nutritional and Quality of Life Aspects. Acta OncolÃ³gica, 1992, 31, 823-831.	0.8	14
65	Serum erythropoietin in the diagnosis of polycythaemia and after phlebotomy treatment. British Journal of Haematology, 1992, 81, 603-606.	1.2	65
66	Serum erythropoietin in rheumatoid arthritis and other inflammatory arthritides: relationship to anaemia and the effect of antiâ€inflammatory treatment. British Journal of Haematology, 1987, 65, 479-483.	1.2	62
67	SUBCELLULAR CHARACTERIZATION OF THE TRANSFERRINâ€TRANSFERRIN RECEPTOR AND IRON ACCUMULATING SYSTEM OF ESTABLISHED HUMAN ERYTHROID AND MONOBLASTOID TUMOUR CELL LINES. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1986, 94A, 245-252.	0.3	1
68	Regulation of Iron Therapy by S-Ferritin Estimations in Patients on Chronic Hemodialysis. Scandinavian Journal of Urology and Nephrology, 1981, 15, 69-72.	1.4	7
69	Serum Ferritin in Ethiopian Mothers and their Newborn Infants. Relation to Iron Intake and Socioâ€Economic Conditions. Scandinavian Journal of Haematology, 1981, 27, 247-252.	0.0	17
70	Serum Ferritin in the Regulation of Iron Therapy in Blood Donors. Vox Sanguinis, 1980, 38, 29-35.	0.7	18
71	Cerebrospinal fluid ferritin in patients with cerebral infarction or bleeding. Acta Neurologica Scandinavica, 1980, 61, 384-392.	1.0	34
72	Serum Ferritin during Inflammation A Study on Myocardial Infarction. Acta Medica Scandinavica, 1979, 206, 361-366.	0.0	20

#	Article	IF	Citations
73	Serum Ferritin Levels in Male Blood Donors. Vox Sanguinis, 1978, 34, 65-70.	0.7	36
74	Serum Ferritin and Erythrocyte 2,3â€ÐPG during Quantitated Phlebotomy and Iron Treatment. Scandinavian Journal of Haematology, 1977, 19, 327-333.	0.0	33